Winner of the ESVS Prize 1988. Effects of prostaglandin E1 (PGE1) on experimental renal ischaemia.
A persisting incidence of acute renal failure has been observed after operative treatment of thoracoabdominal aortic aneurysm, ruptured abdominal aortic aneurysm and renal artery occlusive disease in patients with preoperative impairment of renal function. Because preservation of kidney function can play an important role in the outcome of these patients, the effects of prostaglandin E1 (PGE1) to prevent ischaemic renal failure were studied in an experimental model. Twenty dogs were exposed to 3 h warm ischaemia by clamping of the supra- and infrarenal aorta and both renal arteries. In 10 dogs PGE1 was given intravenously (100 ng/kg/min) for 15 min before clamping. Ten dogs treated with normal saline served as controls. Glomerular filtration rate, renal plasma flow, plasma creatinine, blood urea nitrogen, urine volume, free water clearance and renovascular resistance were calculated before and after renal ischaemia for both groups. The dogs were followed-up for 2 weeks and radionuclide studies with Tc-99m-MAG3, I-131-OIH and In-113m-DTPA were performed on the third postoperative day to calculate global and split renal clearance, tracer extraction fraction and mean transport time. After renal ischemia 9 dogs of the control group and 3 dogs of the PGE1-group developed acute renal failure (P less than 0.05 due to Fisher's exact text). PGE1 infusion significantly attenuated the postischaemic fall in glomerular filtration rate and renal concentrating ability as well as the postischaemic increase of plasma creatinine and blood urea nitrogen induced by 3 h warm renal ischaemia (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Torsello
G
G
Department of Vascular Surgery and Renal Transplantation, University of Düsseldorf, West Germany.
Schrör
K
K
Szabo
Z
Z
Kutkuhn
B
B
Strobach
H
H
Godehardt
E
E
Sandmann
W
W
D058186:Acute Kidney Injury / Q000000981:diagnostic imaging / Q000378:metabolism / Q000517:prevention & control*; D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D001363:Awards and Prizes; D001806:Blood Urea Nitrogen; D004195:Disease Models, Animal; D004285:Dogs; D005060:Europe; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D007511:Ischemia / Q000000981:diagnostic imaging / Q000378:metabolism / Q000517:prevention & control*; D007668:Kidney / Q000098:blood supply*; D007671:Kidney Concentrating Ability / Q000187:drug effects; D011877:Radionuclide Imaging; D012083:Renin / Q000097:blood; D012955:Societies, Medical; D013929:Thromboxane B2 / Q000652:urine; D014655:Vascular Resistance / Q000187:drug effects; D014656:Vascular Surgical Procedures
D013929:Thromboxane B2; D012083:Renin; D000527:Alprostadil